These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 16565167)

  • 1. Antinociceptive pharmacology of N-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-2-[2-[[(4-methoxy-2,6-dimethylphenyl) sulfonyl]methylamino]ethoxy]-N-methylacetamide, fumarate (LF22-0542), a novel nonpeptidic bradykinin B1 receptor antagonist.
    Porreca F; Vanderah TW; Guo W; Barth M; Dodey P; Peyrou V; Luccarini JM; Junien JL; Pruneau D
    J Pharmacol Exp Ther; 2006 Jul; 318(1):195-205. PubMed ID: 16565167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antihyperalgesic effects of (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats.
    Lehto SG; Tamir R; Deng H; Klionsky L; Kuang R; Le A; Lee D; Louis JC; Magal E; Manning BH; Rubino J; Surapaneni S; Tamayo N; Wang T; Wang J; Wang J; Wang W; Youngblood B; Zhang M; Zhu D; Norman MH; Gavva NR
    J Pharmacol Exp Ther; 2008 Jul; 326(1):218-29. PubMed ID: 18420600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
    Whiteside GT; Gottshall SL; Boulet JM; Chaffer SM; Harrison JE; Pearson MS; Turchin PI; Mark L; Garrison AE; Valenzano KJ
    Eur J Pharmacol; 2005 Dec; 528(1-3):65-72. PubMed ID: 16316650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SSR240612 [(2R)-2-[((3R)-3-(1,3-benzodioxol-5-yl)-3-[[(6-methoxy-2-naphthyl)sulfonyl]amino]propanoyl)amino]-3-(4-[[2R,6S)-2,6-dimethylpiperidinyl]methyl]phenyl)-N-isopropyl-N-methylpropanamide hydrochloride], a new nonpeptide antagonist of the bradykinin B1 receptor: biochemical and pharmacological characterization.
    Gougat J; Ferrari B; Sarran L; Planchenault C; Poncelet M; Maruani J; Alonso R; Cudennec A; Croci T; Guagnini F; Urban-Szabo K; Martinolle JP; Soubrié P; Finance O; Le Fur G
    J Pharmacol Exp Ther; 2004 May; 309(2):661-9. PubMed ID: 14747609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological, pharmacokinetic, and primate analgesic efficacy profile of the novel bradykinin B1 Receptor antagonist ELN441958.
    Hawkinson JE; Szoke BG; Garofalo AW; Hom DS; Zhang H; Dreyer M; Fukuda JY; Chen L; Samant B; Simmonds S; Zeitz KP; Wadsworth A; Liao A; Chavez RA; Zmolek W; Ruslim L; Bova MP; Holcomb R; Butelman ER; Ko MC; Malmberg AB
    J Pharmacol Exp Ther; 2007 Aug; 322(2):619-30. PubMed ID: 17470643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of kinin B1 and B2 receptors in a rat model of neuropathic pain.
    Petcu M; Dias JP; Ongali B; Thibault G; Neugebauer W; Couture R
    Int Immunopharmacol; 2008 Feb; 8(2):188-96. PubMed ID: 18182225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antihyperalgesic activity of a novel nonpeptide bradykinin B1 receptor antagonist in transgenic mice expressing the human B1 receptor.
    Fox A; Kaur S; Li B; Panesar M; Saha U; Davis C; Dragoni I; Colley S; Ritchie T; Bevan S; Burgess G; McIntyre P
    Br J Pharmacol; 2005 Apr; 144(7):889-99. PubMed ID: 15685199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A-740003 [N-(1-{[(cyanoimino)(5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat.
    Honore P; Donnelly-Roberts D; Namovic MT; Hsieh G; Zhu CZ; Mikusa JP; Hernandez G; Zhong C; Gauvin DM; Chandran P; Harris R; Medrano AP; Carroll W; Marsh K; Sullivan JP; Faltynek CR; Jarvis MF
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1376-85. PubMed ID: 16982702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological characterization and radioligand binding properties of a high-affinity, nonpeptide, bradykinin B1 receptor antagonist.
    Ransom RW; Harrell CM; Reiss DR; Murphy KL; Chang RS; Hess JF; Miller PJ; O'Malley SS; Hey PJ; Kunapuli P; Su DS; Markowitz MK; Wallace MA; Raab CE; Jones AN; Dean DC; Pettibone DJ; Freidinger RM; Bock MG
    Eur J Pharmacol; 2004 Sep; 499(1-2):77-84. PubMed ID: 15363953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of kinin B1 receptors in the nociception produced by peripheral protein kinase C activation in mice.
    Ferreira J; Trichês KM; Medeiros R; Cabrini DA; Mori MA; Pesquero JB; Bader M; Calixto JB
    Neuropharmacology; 2008 Mar; 54(3):597-604. PubMed ID: 18164734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects.
    De Vry J; Denzer D; Reissmueller E; Eijckenboom M; Heil M; Meier H; Mauler F
    J Pharmacol Exp Ther; 2004 Aug; 310(2):620-32. PubMed ID: 15140913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired nociception and peripheral opioid antinociception in mice lacking both kinin B1 and B2 receptors.
    Cayla C; Labuz D; Machelska H; Bader M; Schäfer M; Stein C
    Anesthesiology; 2012 Feb; 116(2):448-57. PubMed ID: 22273860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antinociceptive profile of a selective metabotropic glutamate receptor 1 antagonist YM-230888 in chronic pain rodent models.
    Kohara A; Nagakura Y; Kiso T; Toya T; Watabiki T; Tamura S; Shitaka Y; Itahana H; Okada M
    Eur J Pharmacol; 2007 Sep; 571(1):8-16. PubMed ID: 17597604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha.
    LoVerme J; Russo R; La Rana G; Fu J; Farthing J; Mattace-Raso G; Meli R; Hohmann A; Calignano A; Piomelli D
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1051-61. PubMed ID: 16997973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antinociceptive activity of the N-methyl-D-aspartate receptor antagonist N-(2-Indanyl)-glycinamide hydrochloride (CHF3381) in experimental models of inflammatory and neuropathic pain.
    Villetti G; Bergamaschi M; Bassani F; Bolzoni PT; Maiorino M; Pietra C; Rondelli I; Chamiot-Clerc P; Simonato M; Barbieri M
    J Pharmacol Exp Ther; 2003 Aug; 306(2):804-14. PubMed ID: 12750440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antinociceptive effects of the non-selective cannabinoid receptor agonist CP 55,940 are absent in CB1(-/-) and not CB2(-/-) mice in models of acute and persistent pain.
    Sain NM; Liang A; Kane SA; Urban MO
    Neuropharmacology; 2009 Sep; 57(3):235-41. PubMed ID: 19538975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Divergent peripheral effects of pituitary adenylate cyclase-activating polypeptide-38 on nociception in rats and mice.
    Sándor K; Bölcskei K; McDougall JJ; Schuelert N; Reglodi D; Elekes K; Petho G; Pintér E; Szolcsányi J; Helyes Z
    Pain; 2009 Jan; 141(1-2):143-50. PubMed ID: 19091468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats.
    Honore P; Wismer CT; Mikusa J; Zhu CZ; Zhong C; Gauvin DM; Gomtsyan A; El Kouhen R; Lee CH; Marsh K; Sullivan JP; Faltynek CR; Jarvis MF
    J Pharmacol Exp Ther; 2005 Jul; 314(1):410-21. PubMed ID: 15837818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted Mu opioid agonist with antihyperalgesic activity: II. In vivo pharmacological characterization in the rat.
    Whiteside GT; Harrison JE; Pearson MS; Chen Z; Fundytus ME; Rotshteyn Y; Turchin PI; Pomonis JD; Mark L; Walker K; Broglé KC
    J Pharmacol Exp Ther; 2004 Aug; 310(2):793-9. PubMed ID: 15054116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinin B(1) and B(2) receptors contribute to orofacial heat hyperalgesia induced by infraorbital nerve constriction injury in mice and rats.
    Luiz AP; Schroeder SD; Chichorro JG; Calixto JB; Zampronio AR; Rae GA
    Neuropeptides; 2010 Apr; 44(2):87-92. PubMed ID: 19914714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.